April 17, 2026 by Aurigene Tech Team Exceptionally selective and orally bioavailable p300 degraders for the treatment of CBP-mutant and p300-dependent cancers
April 17, 2026 by Aurigene Tech Team Selective degradation of SMARCA4 as a therapeutic strategy in SMARCA4 driven cancers
April 17, 2026 by Aurigene Tech Team Discovery and characterization of once- a- month intravenously and orally bioavailable SMARCA2 degraders for treating SMARCA4 mutant cancers
December 31, 2025 by admin aurigene Novel IL-15 modules promote long-term persistence, repeated tumor killing and self-sustenance of chimeric antigen receptor-natural killer (CAR-NK) cells manufactured using an indigenous platform
November 19, 2025 by admin aurigene Development of a Differentiated, Best-in-Class oral Cbl-b inhibitor with Robust Immune Activation and Favourable Safety for Cancer Immunotherapy
November 19, 2025 by admin aurigene Discovery and preclinical characterization of novel macrocyclic KIF18A inhibitors for treatment of chromosomally instable tumors
November 19, 2025 by admin aurigene Discovery and development of a highly differentiated, efficacious, first-in-class anti-SIRPα/β dual antibody with single agent phagocytosis activity
November 19, 2025 by admin aurigene Identification of an orally bio-available SMARCA2 selective degrader for treatment of SMARCA4 mutant cancers
June 5, 2025 by admin aurigene Discovery and development of a highly cooperative and potent pan-KRAS degrader
June 5, 2025 by admin aurigene Discovery of highly selective, potent and orally bio-available SMARCA2 degraders
